Razieh Ghodsi
Overview
Explore the profile of Razieh Ghodsi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
295
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yousefian M, Hashemi M, Eskandarpour V, Zarghi A, Hadizadeh F, Ghodsi R
Bioorg Chem
. 2025 Feb;
156:108231.
PMID: 39904079
New series of indolin-2-ones possessing sunitinib scaffold and a hydroxamic acid moiety were designed and synthesized as inhibitors of HDAC, demonstrating significant anti-cancer properties with potential VEGFR inhibition, using sunitinib...
2.
Arami N, Tajani A, Hashemi M, Rezaei T, Ghodsi R, Soheili V, et al.
Mol Biol Rep
. 2025 Jan;
52(1):175.
PMID: 39883336
Background: Pseudomonas aeruginosa's inherent and adapted resistance makes this pathogen a serious problem for antimicrobial treatments. Furthermore, its biofilm formation ability is the most critical armor against antimicrobial therapy, and...
3.
Omidkhah N, Gheisari A, Oskuei S, Chamani J, Hadizadeh F, Atarodi A, et al.
Bioorg Chem
. 2025 Jan;
154:108098.
PMID: 39753040
In this study, novel 2-styrylquinoline derivatives possessing a planar aromatic system and a flexible side chain with an amino substituent were designed and synthesized as DNA-intercalating antitumor agents. The cytotoxic...
4.
Goudarzi S, Vosough Ghanbari M, Rohani J, Ghodsi R, Rassouli F
J Chemother
. 2024 Oct;
:1-10.
PMID: 39375926
The low survival rate of adult T-cell leukemia/lymphoma (ATL) underscores the critical need for innovative therapeutic agents. While the pharmacokinetics of HDACis have been documented in several hematological neoplasms, there...
5.
Mirzaei S, Eisvand F, Nejabat M, Ghodsi R, Hadizadeh F
Anticancer Agents Med Chem
. 2024 Apr;
24(3):185-192.
PMID: 38629154
Background: In a previous work from the author of this study, the compound of 9IV-c, ((E)-2-(3,4- dimethoxystyryl)-6,7,8-trimethoxy-N-(3,4,5-trimethoxyphenyl)quinoline-4-amine) was synthesized, and the effects of potent activity on the multiple human tumor...
6.
Omidkhah N, Hadizadeh F, Ghodsi R, Kesharwani P, Sahebkar A
Curr Drug Discov Technol
. 2024 Mar;
21(6):e050324227669.
PMID: 38445698
Introduction: Numerous clinical trials are currently investigating the potential of nitric oxide (NO) as an antiviral agent against coronaviruses, including SARS-CoV-2. Additionally, some researchers have reported positive effects of certain...
7.
Tajani A, Soheili V, Moosavi F, Ghodsi R, Alizadeh T, Bazzaz B
Anal Chim Acta
. 2022 Mar;
1199:339574.
PMID: 35227378
Here a highly selective molecular imprinting polymer was developed to attenuate biofilm formation of the multidrug-resistant pathogen Pseudomonas aeruginosa by disrupting the intermolecular signaling system. Firstly, a dummy template molecular...
8.
Hadizadeh F, Ghodsi R, Mirzaei S, Sahebkar A
Comput Math Methods Med
. 2022 Jan;
2022:4004068.
PMID: 35075369
Microtubules play a critical role in mitosis and cell division and are regarded as an excellent target for anticancer therapy. Although microtubule-targeting agents have been widely used in the clinical...
9.
Mirzaei S, Ghodsi R, Hadizadeh F, Sahebkar A
Biomed Res Int
. 2022 Jan;
2022:9761279.
PMID: 35036443
[This corrects the article DOI: 10.1155/2021/6480804.].
10.
Omidkhah N, Ghodsi R
Eur J Med Chem
. 2021 Oct;
227:113934.
PMID: 34700268
HDAC inhibitors and NO donors have both demonstrated independently broad therapeutic potential in a variety of diseases. Borretto et al. presented the topic of NO-HDAC dual inhibitors for the first...